Mylan Knocks Ranbaxy's Exclusivity Right For Valsartan
By Maria Chutchian ( October 2, 2012, 10:29 PM EDT) -- Mylan Pharmaceuticals Inc. on Tuesday hit the U.S. Food and Drug Administration with a lawsuit objecting to its award of a 180-day exclusivity period to Ranbaxy Pharmaceuticals Inc. for the marketing of a generic version of hypertension drug valsartan....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.